Is NCT07720375 recruiting in Brandon, FL?

Yes, NCT07720375 is currently recruiting participants at its Brandon, FL location. This non-cystic fibrosis bronchiectasis clinical trial is actively enrolling qualified participants.

Is participation in this Brandon clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Non-cystic Fibrosis Bronchiectasis Clinical Trial in Brandon, FL

Q: How do I join the non-cystic fibrosis bronchiectasis clinical trial in Brandon?

To join this clinical trial in Brandon, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Who Can Participate

Inclusion Criteria

Participant must be 18 to ≤80 years of age, inclusive, at the time of signing the informed consent form (ICF)

Participant with a documented history of Non-Cystic Fibrosis Bronchiectasis (NCFB) (cough, chronic sputum production, and/or recurrent respiratory infections) confirmed by high resolution computed tomography (HRCT) demonstrating bronchiectasis in 1 or more lobes. Confirmation of diagnosis via HRCT will be performed as close as possible to, and within 7 calendar days of the Baseline visit, in all participants who meet all inclusion criteria and no

Exclusion Criteria

at Screening. Central reading confirmation, where images are evaluated by independent centralized experts, is required before the participant is randomized

Participant with a history of chronic expectoration who are current sputum producers and are able to provide spontaneous sputum sample at Screening. If the participant is unable to produce spontaneous sputum at Screening, the participant will be considered a screening failure and may be rescreened once

Participant with a history of at least 2 moderate or severe pulmonary exacerbations within the past 12 months prior to Screening or 1 severe pulmonary exacerbation within 6 months prior to Screening

Participant with post- Bronchodilator (BD) forced expiratory volume (FEV) 1% predicted ≥30% at Screening and Baseline

Participant has acceptable inhaler (where applicable) and spirometry techniques according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines during the Screening Visit. Participants who do not meet such criteria can be repeated once without being rescreened

Participant can be male or female

A male participant must agree to use contraception during the Intervention Period and for at least 60 days after the final dose of study intervention, and refrain from donating sperm during this period

A female participant is eligible to\[ participate if she is not pregnant, not breastfeeding (including pumping breastmilk to feed a child), and at least 1 of the following conditions applies:

Not a woman of childbearing potential (WOCBP) OR

A WOCBP who agrees to follow the contraceptive guidance during the Intervention Period and for at least 60 days after the final dose of study intervention Exclusion Criteria:

Participant has any history or presence of any medical or psychiatric condition, physical examination finding, laboratory test result, or Electrocardiogram (ECG) signal that, in the opinion of the investigator, could constitute a risk when taking the study intervention; or interfere with the interpretation of data and could jeopardize or would compromise the study participant's ability to participate in this study

Participant has a presence or family history (first degree) of inflammatory bowel disease (IBD) (includes Crohn's disease and ulcerative colitis)

Participant has a history of chronic or recurrent clinically significant infections, or a serious extrapulmonary infection within 6 months prior to the Baseline, as judged by the investigator.

Participant is not permitted to enroll into the study if they meet any of the following Tuberculosis (TB) exclusion criteria:

Known active TB disease.

History of active TB involving any organ system unless adequately treated according to World Health Organization/Centers for Disease Control and Prevention therapeutic guidance and proven to be fully recovered upon consultation with an appropriate relevant specialist

Latent tuberculosis infection (LTBI) (unless a course of appropriate preventative therapy has been completed prior to study intervention dosing). TB preventive therapy should be in accordance with applicable clinical guidelines and appropriate specialist judgment based on the origin of the infection

High risk of acquiring TB infection

Participant has clinically important pulmonary disease other than NCFB as judged by the investigator.

Participant has an acute infection (including pulmonary infection) requiring antibiotics, systemic corticosteroids, or antiviral medication within 4 weeks prior to Screening (and in the Screening Period) based on the final day of antibiotic/antiviral/systemic steroid treatment or hospitalization discharge date, whichever occurred later. A participant who suffers from a pulmonary exacerbation during the Screening Period, prior to randomization, is considered a screen failure. Rescreening is allowed once following resolution of the pulmonary exacerbation

Participant has bronchiectasis known to be due to lung fibrosis, cystic fibrosis, hypogammaglobulinemia, common variable immunodeficiency disorders or α1-antitrypsin deficiency

Participant has a primary diagnosis of Chronic Obstructive Pulmonary Disease (COPD) or asthma. A secondary diagnosis is allowed

Participant has significant hemoptysis defined as ≥300mL or requiring blood transfusion within 6 weeks from Screening

Participant has a history of lung transplantation

Study participant has an absolute neutrophil count (ANC) \<1.5×103/μL. This test can be repeated once

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Brandon?

Yes, this clinical trial (NCT07720375) has an active research site in Brandon, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Non-cystic Fibrosis Bronchiectasis Treatment Options in Brandon, FL

If you're searching for non-cystic fibrosis bronchiectasis treatment options in Brandon, FL, this clinical trial (NCT07720375) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Brandon research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced non-cystic fibrosis bronchiectasis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all non-cystic fibrosis bronchiectasis clinical trials near you to find additional studies recruiting in your area.

Non-cystic Fibrosis Bronchiectasis Clinical Trial in Brandon, FL

Expert Care in Brandon

IRB Approved

No-Cost Care

Apply for This Brandon Location

Why Participate?

Simple Process

About This Non-cystic Fibrosis Bronchiectasis Study in Brandon